Application Value of Lung-Fire-Clearing,Phlegm-Resolving,and Bowels-Relaxing Decoction in Treating Lung Cancer of Phlegm-Heat Pattern

Objective:This article explores the clinical effects of lung-fire-clearing,phlegm-resolving and bowels-relaxing decoction in the treatment of lung cancer of phlegm-heat pattern.Methods:A total of 6 cases of lung cancer patients with phlegm-heat pattern were randomly selected from Inner Mongolia Baicaotang Qin's Zhong Meng Medical Hospital from March 2018 to December 2020 to conduct the study.They were divided into the reference group and the study group by using the digital table method.The patients in the reference group were treated with conventional Western medicine whereas the patients in the study group were treated with lung-fire-clearing,phlegm-resolving,and bowels-relaxing decoction to observe the curative effect.Results:There were no significant differences in the levels of the tumor markers between the two groups before treatment(P>0.05).However,after treatment,the levels of cytokeratin 19 soluble fragments(CYFRA21-1),carbohydrate antigen 125(CA125),and carcinoembryonic antigen(CEA)in the study group were lower than those in the control group(P<0.05).The effective rate and the quality of life score of the study group were higher than those of the reference group while the incidence of adverse reactions was lower than that of the reference group,P<0.05.Conclusion:Lung-fire-clearnig,phlegm-resolving,and bowels-relaxing decoction can effectively improve the symptoms of patients with lung cancer and improve their quality of life.

宣肺固金汤治疗痰热蕴肺型卒中相关性肺炎疗效及对炎症因子、免疫功能的影响

目的观察宣肺固金汤治疗痰热蕴肺型卒中相关性肺炎(SAP)的临床疗效及对炎症因子和免疫功能的影响。方法选取2022年6月—2024年2月在佳木斯市中医医院急诊科及黑龙江中医药大学附属第二医院康复科治疗的SAP患者91例,按随机数字表法将患者分为观察组(45例,脱落3例)和对照组(46例,脱落4例),对照组给予营养支持、肺功能训练、注射用哌拉西林钠他唑巴坦钠抗感染(根据药敏调整抗生素)等常规综合治疗,观察组在对照组治疗基础上给予宣肺固金汤治疗,2组疗程均为14 d。比较2组患者治疗前后中医证候积分、临床肺部感染评分(CPIS)及血清降钙素原(PCT)、高敏C反应蛋白(hs-CRP)、免疫球蛋白(IgA、IgM、IgG)、T淋巴细胞亚群(CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))水平,统计2组临床疗效及不良反应发生率。结果治疗后2组患者中医证候积分、CPIS评分及血清PCT、hs-CRP、CD8^(+)水平均明显降低(P均<0.05),血清IgA、IgM、IgG、CD4^(+)、CD4^(+)/CD8^(+)均明显升高(P均<0.05),且观察组上述各项指标改善情况均明显优于对照组(P均<0.05);观察组总有效率明显高于对照组[92.86%(39/42)比80.95%(34/42),P<0.05],2组不良反应发生率比较差异无统计学意义(P>0.05)。结论西医联合宣肺固金汤治疗痰热蕴肺型SAP综合疗效优于单纯西医治疗,更有利于减轻肺部感染程度,降低炎症因子水平,增强机体免疫功能。

儿童变应性鼻炎中医证候规律研究

[目的]初步探索儿童变应性鼻炎(allergic rhinitis,AR)中医证候分布规律,为制定儿童AR辨证分型标准提供依据。[方法]对2015年6月至2015年9月上海交通大学医学院附属儿童医学中心耳鼻喉科及中医科门诊的184例AR患儿进行中医证候调查,分析中医证型及证素分布规律。[结果]184例患儿中肺虚感寒型占34.24%、肺脾气虚型占23.91%、肺经郁热型占23.37%、肾阳亏虚型占18.48%。出现频次最多的证素依次为鼻甲肿胀、鼻塞、清涕、涕多、打喷嚏、鼻黏膜淡白、脉细弱、久病不愈、嗅觉迟钝和鼻痒。[结论]AR患儿最常见的中医证型是肺虚感寒型,最常见证素是鼻甲肿胀;儿童AR的证候规律仍需大样本临床研究进一步总结。

Efficacy and safety of Qingfei Huatan formula in the treatment of acute exacerbation of chronic obstructive pulmonary disease:A multi-centre,randomised,double-blind,placebo-controlled trial

Background Chronic obstructive pulmonary disease(COPD),a common respiratory disease,can be effectively treated by traditional Chinese medicine(TCM).Qingfei Huatan,a TCM formula,has been reported to effectively alleviate the clinical symptoms of COPD patients.However,there is a lack of multi-centre,randomised,double-blind,controlled clinical trials documenting the clinical efficacy and safety of this formula in the treatment of acute exacerbation of COPD(AECOPD).Objective This study evaluated the efficacy and safety of Qingfei Huatan formula in the treatment of AECOPD,thereby providing high-quality clinical evidence.Design,setting,participants and interventions A total of 276 patients with AECOPD were included in this multi-centre,randomised,double-blind,placebo-controlled trial and were randomised into treatment and control groups at a ratio of 1:1.Patients in the treatment and control groups took Qingfei Huatan granules or simulated Qingfei Huatan granules twice a day,for 14 days,in addition to Western medicine treatment.All patients were followed up for 3 months.Main outcome measures The primary outcome was time taken to symptom stabilisation.The secondary outcomes included duration of antibiotic use,clinical symptom and sign score,TCM syndrome score,dyspnoea score,and quality of life(QOL)score.Meanwhile,the safety of the formula was assessed through routine urine and stool tests,electrocardiograms,liver and kidney function tests,and the observation of adverse events throughout the trial.Results The time taken for effective stabilisation(P<0.05)and obvious stabilisation(P<0.01),and the duration of antibiotic use(P<0.05)were significantly shorter in the treatment group than in the control group.On days 6,9,12 and 14 of treatment,clinical symptom and sign score decreased in both groups,particularly in the treatment group(P<0.01).On days 9,12 and 14 of treatment,the TCM syndrome scores of both groups were reduced(P<0.01),with more significant reductions in the treatment group.At 3 months after the end of treatment,the treatment group continued to have lower clinical symptom and sign score and TCM syndrome score than the control group(P<0.01).On days 6,9,12 and 14 of treatment,dyspnoea and QOL scores were markedly reduced in the two groups(P<0.05 and P<0.01,respectively),especially in the treatment group.At 3 months after the end of treatment,dyspnoea and QOL scores were lower in the treatment group than those in the control group(P<0.01).No serious adverse events were observed in either group.Conclusion The Qingfei Huatan formula can effectively shorten the duration of AECOPD and antibiotic use,significantly relieve clinical symptoms,and increase QOL for AECOPD patients,with a favourable safety profile.These results suggest that this formula can be used as a complementary treatment for AECOPD patients.

清肺化痰汤治疗慢性阻塞性肺疾病急性加重期痰热壅肺证的临床研究

目的探讨清肺化痰汤治疗慢性阻塞性肺疾病(简称慢阻肺)急性加重期痰热壅肺证的免疫调节机制。方法将64例慢阻肺急性加重期痰热壅肺证患者随机分为治疗组及对照组。对照组给予抗感染、平喘、必要时机械通气治疗;治疗组在对照组治疗的基础上口服清肺化痰汤中药颗粒剂,连续治疗7 d。观察治疗前后患者咳嗽、咯痰、喘息、气短、自汗、哮鸣音、神疲懒言、食少纳呆、食后腹胀等症状变化及临床总体疗效;比较治疗前后患者分化簇4^+分化簇25^+叉头状转录因子P3^+调节性T细胞(CD4^+CD25^+Foxp3^+Treg细胞)、辅助性T细胞17(Th17)百分比,Toll样受体4信使核糖核酸(TLR4 mRNA)的表达量,血清白细胞介素-8(IL-8)、中性粒细胞弹性蛋白酶(NE)、肿瘤坏死因子-α(TNF-α)含量,核转录因子kappa B(NF-κB)的吸光度。结果治疗后2组患者的临床症状均有明显改善。治疗组较对照组咯痰、喘息、气短、哮鸣音、食后腹胀等症状明显改善(P<0.05);治疗组控显率明显高于对照组(P<0.05)。治疗组患者血清NE、TNF-α浓度;全血TLR4 mRNA表达,外周血中Th17百分比较对照组显著降低(P<0.05)。结论清肺化痰汤联合西药治疗较单用西药能更好的改善慢阻肺急性加重期患者临床症状,结合动物实验研究推测清肺化痰汤可能通过调节固有免疫中TLR4-MyD88/TRIF-NF-κB信号传导通路及Th17介导的获得性免疫干预慢阻肺急性加重期炎症反应。